News for hackers. Stuff that matters.
Re:A Dying Scientist and His Rogue Vaccine Trial by Fomite on Thursday May 03, 2018 @01:26PM (#16987885)
While commonly used as an example, I'll note this isn't actually even always true for antibiotics.

The development of Fidaxomicin/Difficid is actually an example of a fairly inexpensive clinical trial (by clinical trial standards), and Merck didn't buy Cubist for $9.5 billion for a drug they don't think will recover their outlay.

There are no comments on this comment yet.